TY - JOUR
T1 - Genetic and environmental factors underlying the rapid changes in epidemiological and clinical features of multiple sclerosis and neuromyelitis optica in Japanese
AU - Kira, Jun Ichi
PY - 2013/12
Y1 - 2013/12
N2 - The discovery of a specific biomarker for neuromyelitis optica (NMO), NMO-immunoglobulin G (IgG)/anti-aquaporin-4 (AQP4) antibody, requires us to take it into account when interpreting epidemiological findings on multiple sclerosis (MS). Recent genetic studies showed that HLA-DRB1*0405 is the most common susceptibility allele for non-NMO MS in Japanese, and that DRB1*0405 carriers comprise >40% of all Japanese MS patients. Thus, idiopathic central nervous system demyelinating disease in Japanese can be subclassified into DRB1*0405-positive and -negative MS, and anti-AQP4 antibody-positive and -negative NMO. HLA-DRB1*0405-positive MS patients show younger age at onset, fewer brain lesions and a slower progression. The recent increase in the numbers of MS patients in this subgroup could explain the decrease in age at onset, as shown by the fourth nationwide survey in Japanese MS patients. Among HLA-DRB1*0405-negative MS patients, DRB1*1501 is a risk factor for MS, and DRB1*1501 carriers have high frequencies of brain lesions fulfilling the Barkhof criteria and cerebrospinal fluid IgG abnormalities. HLA-DRB1*0405-negative MS patients have higher frequencies of Epstein-Barr virus infection, but a lower frequency of Helicobacter pylori infection, which reflects improved sanitation in childhood. Anti-AQP4 antibody-positive NMO is associated with H. pylori and Chlamydia pneumoniae infections. The effects of improved sanitation on this subgroup might explain the decrease in incidence of opticospinal MS with longitudinally extensive spinal cord lesions, regarded as the same disease as NMO, as suggested by the fourth nationwide survey. Therefore, changes in environmental factors could have differentially influenced susceptibility to each disease subtype in Japanese.
AB - The discovery of a specific biomarker for neuromyelitis optica (NMO), NMO-immunoglobulin G (IgG)/anti-aquaporin-4 (AQP4) antibody, requires us to take it into account when interpreting epidemiological findings on multiple sclerosis (MS). Recent genetic studies showed that HLA-DRB1*0405 is the most common susceptibility allele for non-NMO MS in Japanese, and that DRB1*0405 carriers comprise >40% of all Japanese MS patients. Thus, idiopathic central nervous system demyelinating disease in Japanese can be subclassified into DRB1*0405-positive and -negative MS, and anti-AQP4 antibody-positive and -negative NMO. HLA-DRB1*0405-positive MS patients show younger age at onset, fewer brain lesions and a slower progression. The recent increase in the numbers of MS patients in this subgroup could explain the decrease in age at onset, as shown by the fourth nationwide survey in Japanese MS patients. Among HLA-DRB1*0405-negative MS patients, DRB1*1501 is a risk factor for MS, and DRB1*1501 carriers have high frequencies of brain lesions fulfilling the Barkhof criteria and cerebrospinal fluid IgG abnormalities. HLA-DRB1*0405-negative MS patients have higher frequencies of Epstein-Barr virus infection, but a lower frequency of Helicobacter pylori infection, which reflects improved sanitation in childhood. Anti-AQP4 antibody-positive NMO is associated with H. pylori and Chlamydia pneumoniae infections. The effects of improved sanitation on this subgroup might explain the decrease in incidence of opticospinal MS with longitudinally extensive spinal cord lesions, regarded as the same disease as NMO, as suggested by the fourth nationwide survey. Therefore, changes in environmental factors could have differentially influenced susceptibility to each disease subtype in Japanese.
UR - http://www.scopus.com/inward/record.url?scp=84890844135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890844135&partnerID=8YFLogxK
U2 - 10.1111/cen3.12034
DO - 10.1111/cen3.12034
M3 - Review article
AN - SCOPUS:84890844135
SN - 1759-1961
VL - 4
SP - 261
EP - 273
JO - Clinical and Experimental Neuroimmunology
JF - Clinical and Experimental Neuroimmunology
IS - 3
ER -